Michael has made over 10 trades of the Nektar Therapeutics stock since 2005, according to the Form 4 filled with the SEC. Most recently Michael bought 23,200 units of NKTR stock worth $495,784 on 21 August 2015.
The largest trade Michael's ever made was exercising 107,420 units of Nektar Therapeutics stock on 14 September 2012 worth over $1,665,010. On average, Michael trades about 6,596 units every 90 days since 2003. As of 21 August 2015 Michael still owns at least 450,847 units of Nektar Therapeutics stock.
You can see the complete history of Michael Brown stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is 20330 STEVENS CREEK BOULEVARD, , CUPERTINO, CA, 95014.
Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie, eJohn Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Nektar Therapeutics executives and other stock owners filed with the SEC include: